VP, Search & Evaluation, Corporate Development
Daniel is a VP at Gilead Sciences and leads the Search and Evaluation group in Corporate Development. He has thirty years of R&D experience encompassing scientific and/or leadership roles across multiple therapeutic areas and disciplines including Oncology, Inflammation, Virology, Toxicology and Pathology. He started his professional career as a veterinarian and subsequently completed a PhD investigating the immune control of lentiviral infection in horses while concomitantly completing a Pathology residency with subsequent Board certification. He joined the NIH in 1993 and transitioned to Biotech, Genentech in 1995, Millenium in 2002, and Gilead in 2004. Daniel formed and leads the Search and Evaluation group responsible for sourcing, evaluation, and deep diligence of external opportunities across all therapeutic areas including Oncology, Inflammation, Cell Therapy, Virology and Technologies/Platforms. The group’s efforts span both early and late stage partnerships and/or acquisitions exemplified by transactions with Kite, Immunomedics, Arcus, Dragonfly, Xinthera, MiroBio, Tango, Tentarix, Xilio, CymaBay, Merus, Terray, Leo Pharma and more.